Drug Trial Radar · NCT00803972
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
Last checked: Nov 20, 2026Latest source record: Aug 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Nov 2008
Primary completion
Aug 28, 2009
Study completion Aug 28, 2009
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center, Phase I, open-label, single-blind (subjects blinded to the contents of each injection), 4 stage study designed to determine the PK, GD, safety, tolerability, and optimal ratio of rHuPH20 administered with fixed Humulin R or Humalog doses in healthy subjects.
Conditions
- Healthy Volunteers
Interventions
rHuPH20Drug
recombinant human hyaluronidase PH20
Insulin Human InjectionDrug
injection
Insulin Lispro InjectionDrug
injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Insulin AUCTime frame: 0 to 60 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
dgd Research, Inc.
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.